Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 549 citing articles:

Cancer immunotherapy via dendritic cells
Karolina Palucka, Jacques Banchereau
Nature reviews. Cancer (2012) Vol. 12, Iss. 4, pp. 265-277
Open Access | Times Cited: 1843
Coronaviruses — drug discovery and therapeutic options
Alimuddin Zumla, Jasper Fuk‐Woo Chan, Esam I. Azhar, et al.
Nature Reviews Drug Discovery (2016) Vol. 15, Iss. 5, pp. 327-347
Open Access | Times Cited: 1727
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf, Sabrina Kuttruff-Coqui, Katrin Frenzel, et al.
Nature (2018) Vol. 565, Iss. 7738, pp. 240-245
Open Access | Times Cited: 774
Dendritic cell-based immunotherapy
Rachel Lubong Sabado, Sreekumar Balan, Nina Bhardwaj
Cell Research (2016) Vol. 27, Iss. 1, pp. 74-95
Open Access | Times Cited: 759
Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
Hideho Okada, Michael Weller, Raymond Y. Huang, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 15, pp. e534-e542
Open Access | Times Cited: 677
Clinical use of dendritic cells for cancer therapy
Sébastien Anguille, Evelien Smits, Eva Lion, et al.
The Lancet Oncology (2014) Vol. 15, Iss. 7, pp. e257-e267
Closed Access | Times Cited: 639
Therapeutic cancer vaccines: past, present, and future.
Chunqing Guo, Masoud H. Manjili, John R. Subjeck, et al.
Europe PMC (PubMed Central) (2013) Vol. 119, pp. 421-75
Open Access | Times Cited: 559
Immunotherapy for glioma: Current management and future application
Shengchao Xu, Lu Tang, Xizhe Li, et al.
Cancer Letters (2020) Vol. 476, pp. 1-12
Open Access | Times Cited: 559
Brain immunology and immunotherapy in brain tumours
John H. Sampson, Michael D. Gunn, Peter E. Fecci, et al.
Nature reviews. Cancer (2019) Vol. 20, Iss. 1, pp. 12-25
Open Access | Times Cited: 532
Glioma targeted therapy: insight into future of molecular approaches
Keyang Yang, Zhijing Wu, Hao Zhang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 486
Direct Effects of Type I Interferons on Cells of the Immune System
Sandra Hervás‐Stubbs, Jose Luis Pérez‐Gracia, Ana Rouzaut, et al.
Clinical Cancer Research (2011) Vol. 17, Iss. 9, pp. 2619-2627
Closed Access | Times Cited: 463
Clinical relevance of tumour-associated macrophages
Mikaël J. Pittet, Olivier Michielin, Denis Migliorini
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 402-421
Closed Access | Times Cited: 460
Classification of current anticancer immunotherapies
Lorenzo Galluzzi, Erika Vacchelli, José Manuel Bravo‐San Pedro, et al.
Oncotarget (2014) Vol. 5, Iss. 24, pp. 12472-12508
Open Access | Times Cited: 440
Rapid generation of a mouse model for Middle East respiratory syndrome
Jincun Zhao, Kun Li, Christine Wohlford-Lenane, et al.
Proceedings of the National Academy of Sciences (2014) Vol. 111, Iss. 13, pp. 4970-4975
Open Access | Times Cited: 424
Immunotherapy of cancer in 2012
John M. Kirkwood, Lisa H. Butterfield, Ahmad A. Tarhini, et al.
CA A Cancer Journal for Clinicians (2012) Vol. 62, Iss. 5, pp. 309-335
Open Access | Times Cited: 417
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
Gary Kohanbash, Diego Carrera, Shruti Shrivastav, et al.
Journal of Clinical Investigation (2017) Vol. 127, Iss. 4, pp. 1425-1437
Open Access | Times Cited: 365
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Surasak Phuphanich, Christopher J. Wheeler, Jeremy Rudnick, et al.
Cancer Immunology Immunotherapy (2012) Vol. 62, Iss. 1, pp. 125-135
Open Access | Times Cited: 362
Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy
Thiago A. Patente, Mariana Pereira Pinho, Aline A. Oliveira, et al.
Frontiers in Immunology (2019) Vol. 9
Open Access | Times Cited: 347
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Ignacio Melero, Eduardo Castañón, Maite Álvarez, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 9, pp. 558-576
Open Access | Times Cited: 344
Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
Kalijn F. Bol, Gerty Schreibelt, Winald R. Gerritsen, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 8, pp. 1897-1906
Open Access | Times Cited: 336
Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy
Melissa G. Lechner, Saman S. Karimi, Keegan Barry-Holson, et al.
Journal of Immunotherapy (2013) Vol. 36, Iss. 9, pp. 477-489
Open Access | Times Cited: 328
Therapeutic targeting of EPH receptors and their ligands
Andy Boyd, Perry F. Bartlett, Martin Lackmann
Nature Reviews Drug Discovery (2013) Vol. 13, Iss. 1, pp. 39-62
Closed Access | Times Cited: 328
The challenge and prospect of mRNA therapeutics landscape
Yuhua Weng, Chunhui Li, Tongren Yang, et al.
Biotechnology Advances (2020) Vol. 40, pp. 107534-107534
Closed Access | Times Cited: 315
Current State of Immunotherapy for Treatment of Glioblastoma
Tresa McGranahan, Kate E. Therkelsen, Sarah Ahmad, et al.
Current Treatment Options in Oncology (2019) Vol. 20, Iss. 3
Open Access | Times Cited: 277
Therapeutic Cancer Vaccines: Current Status and Moving Forward
J Schlom
JNCI Journal of the National Cancer Institute (2012) Vol. 104, Iss. 8, pp. 599-613
Open Access | Times Cited: 273
Page 1 - Next Page

Scroll to top